Back to Studies

Study analysis · The lancet. Gastroenterology & hepatology · 2020

Think you're safe from fatty liver because you're thin? Think again—40% of NAFLD cases occur in people who are not obese.

You can have fatty liver disease even if you're not overweight, and it can be just as serious as in obese people.

Reading level
Not yet graded certainty
Level 5 · Expert opinionAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

Imagine you're trying to find out if tall kids are better at basketball. You look at lots of different groups of kids and see that, on average, tall kids tend to score more points. This study does that for skinny people with fatty liver — it combines many smaller studies and shows that skinny people with fatty liver also have more health problems. But just like being tall doesn't *cause* you to be good at basketball (maybe they practice more), we can't say that having fatty liver *causes* these health problems. It's just a pattern we see.

What’s the bottom line?

A study combined data from many studies worldwide to find out how common fatty liver disease is in people who are not overweight. They found that about 1 in 8 people have fatty liver even if they have normal weight.

How strong is this study?

The researchers did a good job by searching many places for studies and having two people check each one. But the studies they combined were very different — some used different definitions of 'skinny', some were in different countries, and they were all just watching people over time, not running an experiment. So the results are a bit messy and not super precise. It's like trying to get a final grade by averaging different test scores from different classes — you get a rough idea, but it's not perfectly accurate.

Reporting

40 / 100

  • COI disclosure+40/40
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

0 / 100

  • Randomizationrandomization unclear
  • Blindingblinding unclear
  • Control groupno control group
  • Sample sizeno sample size reported
  • Follow-upno follow-up reported
Publication

100 / 100

Statistical

0 / 100

  • P-valuesno p-values reported
  • Effect sizeno effect size reported
  • Confidence intervalsno confidence intervals
  • Pre-registrationnot pre-registered

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Expert Opinion
Level 5
0

0 / 100

Probability of being correct

Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.

This design cannot establish causation — the findings describe an association, not a cause. This is a systematic review of observational studies (cohort and cross-sectional). While it can identify strong associations, it cannot establish cause-effect relationships due to potential confounding, lack of randomization, and heterogeneity across studies.

No Conflicts

No conflicts of interest identified

Not Disclosed

No conflicts identified.

Undisclosed — Suspicious

The study is a bibliometric analysis; no COI or funding information provided.

Key takeaways

  1. 01

    Around 19% of people with fatty liver are lean, and 41% are non-obese.

  2. 02

    The global prevalence of non-obese fatty liver is 12.1%, and lean fatty liver is 5.1%.

  3. 03

    Each year, about 2.5% of non-obese people develop fatty liver.

  4. 04

    Lean fatty liver often leads to serious liver problems.

  5. 05

    This means fatty liver disease is not just a problem for overweight people; many normal-weight individuals also have it and face health risks.

Surprising findings

  • Nearly 20% of all NAFLD patients are lean (BMI <23 Asian or <25 non-Asian), and over 40% are non-obese.Conventional wisdom dictates that NAFLD is a disease of obesity. Finding such a high proportion in normal-weight individuals contradicts that belief.
  • The incidence of NAFLD in non-obese individuals is 24.6 per 1000 person-years (about 2.5% per year).Many assume that non-obese people are at low risk for developing fatty liver, but this shows a substantial annual incidence comparable to some high-risk groups.

Practical takeaways

If you have a normal BMI but have risk factors like a family history of NAFLD, type 2 diabetes, or elevated liver enzymes, ask your doctor for a liver ultrasound or non-invasive fibrosis test.

This study has high heterogeneity across included studies, and the meta-analysis has published corrections. The confidence is moderate; not every normal-weight person needs screening.

medium confidence

Focus on reducing visceral fat through strength training and a low-glycemic diet rather than just weight loss. Even if your BMI is normal, a waist circumference >35 inches (women) or >40 inches (men) increases risk.

The study did not test interventions; this is inferred from the risk factors identified (central obesity, insulin resistance). Individual results may vary.

medium confidence

Why this study matters

The Hidden Epidemic: One in Eight People with Normal Weight Have Fatty Liver

This meta-analysis of 93 studies from 24 countries found that 12.1% of the general population has non-obese NAFLD, and 5.1% have lean NAFLD. That means over half a billion people worldwide may have fatty liver despite a healthy BMI.

Most people associate fatty liver with obesity, so this statistic challenges a widespread assumption and underscores the need for broader screening.

It's Not Benign: Lean NAFLD Carries Similar Risks to Obese NAFLD

Among non-obese or lean NAFLD patients, 39% have NASH (active liver inflammation), 29.2% have significant fibrosis (scarring), and 3.2% already have cirrhosis. All-cause mortality is 12.1 per 1000 person-years.

Many assume that if you're thin, any liver fat is harmless. This study shows that lean NAFLD can be just as aggressive and deadly as the classic obese phenotype.

Weight Is Not the Only Culprit: Genetics and Visceral Fat Matter More

The study highlights that factors like the PNPLA3 gene variant, central obesity (even with normal BMI), insulin resistance, and gut microbiota play key roles in lean NAFLD. Sarcopenia (loss of muscle mass) is also emerging as a risk factor.

This shifts the narrative from 'eat less, lose weight' to a more complex understanding of metabolic health, giving hope to those who struggle with weight yet still have fatty liver.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.